Innoviva (INVA) Convertible Debt (2010 - 2017)
Innoviva's (INVA) quarterly Convertible Debt came in at $237.9 million in Q2 2017, down 1.47% YoY from $241.4 million in Q2 2016, and little changed on a QoQ basis from $237.7 million in Q1 2017.
Innoviva (INVA) Convertible Debt (2010 - 2017) Analysis & Trends
Innoviva (INVA) has 8 years of Convertible Debt data on file, last reported at $237.9 million in Q2 2017.
- Quarterly Convertible Debt fell 1.47% year-over-year to $237.9 million in Q2 2017, while the trailing twelve-month figure through Jun 2017 was $237.9 million (down 1.47% YoY) and the FY2016 annual result came in at $237.6 million, down 5.34% from the prior year.
- Convertible Debt held at $237.9 million in Q2 2017, from $237.7 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $460.0 million in Q1 2013 to a low of $237.6 million in Q4 2016.
- A 5-year average of $280.2 million and a median of $255.1 million in 2014 frame the typical range for Convertible Debt.
- Annual changes were most pronounced in 2013 — Convertible Debt surged 166.67% — and 2014, when it tumbled 37.5%.
- Tracing INVA's Convertible Debt over 5 years: stood at $287.5 million in 2013, then decreased by 11.27% to $255.1 million in 2014, then declined by 1.61% to $251.0 million in 2015, then retreated by 5.34% to $237.6 million in 2016, then rose by 0.11% to $237.9 million in 2017.
- The last three Convertible Debt figures came in at $237.9 million (Q2 2017), $237.7 million (Q1 2017), and $237.6 million (Q4 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 237.86 Mn |
| Mar 31, 2017 | 237.72 Mn |
| Dec 31, 2016 | 237.60 Mn |
| Sep 30, 2016 | 241.54 Mn |
| Jun 30, 2016 | 241.41 Mn |
| Mar 31, 2016 | 251.12 Mn |
| Dec 31, 2015 | 250.99 Mn |
| Sep 30, 2015 | 255.11 Mn |
| Jun 30, 2015 | 255.11 Mn |
| Mar 31, 2015 | 255.11 Mn |
| Dec 31, 2014 | 255.11 Mn |
| Sep 30, 2014 | 255.11 Mn |
| Jun 30, 2014 | 287.50 Mn |
| Mar 31, 2014 | 287.50 Mn |
| Dec 31, 2013 | 287.50 Mn |
| Sep 30, 2013 | 287.50 Mn |
| Jun 30, 2013 | 459.96 Mn |
| Mar 31, 2013 | 460.00 Mn |
| Dec 31, 2012 | 172.50 Mn |
| Sep 30, 2012 | 172.50 Mn |